根据《专利法》第49条研究药品专利强制许可的可执行性  

Enforceability of drug compulsory license according to the article 49 of Patent Law

作　　者：刘义胜[1] 田侃[1] 

机构地区：[1]南京中医药大学,南京210023

出　　处：《中国新药杂志》2016年第22期2581-2586,共6页Chinese Journal of New Drugs

摘　　要：本文主要研究根据《专利法》第49条启动药品专利强制许可的可执行性。通过分析研究,发现依据我国《专利法》第49条实施药品专利强制许可程序主要存在相关概念模糊、国务院有关主管建议权表述不明、利益相关者没有诉求渠道、审批程序繁琐和费用补偿标准缺失等问题,并提出相应的建议,希望我国能够早日启动药品专利强制许可程序。In this paper, the authors studied the enforceability of starting the compulsory licenses of drug patent according to the Article 49 of Patent Law. Through analysis, it was found that the implementation of compulsory licensing program faces a lot of problems, mainly including fuzzy concepts, unclear statements by the State Council about suggesting right of competent departments, lack of channel for stakeholders demands redress, complicated and cumbersome approval procedures, lack of compensation costs standards and others. Recommendations were made accordingly, hoping China to start the compulsory licensing procedures of drug patent soon.

关 键 词：药品专利 紧急状态 非常情况 公共利益 强制许可 

分 类 号：R95[医药卫生—药学]